Close mobile menu×
Close mobile menu

John P. Bilezikian, MD

Board Certifications: 
Internal Medicine, Endocrinology
Accepting New Patients
Profile Headshot

Schedule an Appointment

Phone Appointments

New and Existing Patients:

Connect Patient Portal

For existing patients, login to make an appointment, view documentation or contact your care provider.

Connect Sign In

Credentials & Experience

America's Top Doctor
NY Top Doctor

Board Certifications

  • Internal Medicine
  • Endocrinology

Clinical Expertise

  • Bone Disease

Education & Training

  • Columbia University College of Physicians and Surgeons
  • Residency: Columbia Presbyterian Medical Center

Honors & Awards

  • L.J. Henderson Prize, Harvard College
  • Alpha Omega Alpha, College of Physicians and Surgeons, Columbia University
  • President, Alumni Association, College of Physicians & Surgeons, 1987-1989
  • Silver Medal, Alumni Association, College of Physicians & Surgeons, 1991
  • Alumni Medal, Alumni Federation of Columbia University, 1993
  • Chair, NIH Consensus Development Panel on Optimal Calcium Intake (1994)
  • Doody Award: THE PARATHYROIDS, (For Best Health Science Books), 1994-1995
  • Doody Award: PRINCIPLES OF BONE BIOLOGY (For Best Health Science Books), 1996-1997)
  • President: American Society of Bone and Mineral Research (1995-1996)
  • Mayo Clinic, Distinguished Lecturer in Medical Science, 1997
  • Distinguished Physician Award of the Endocrine Society, 1998
  • Boy Frame Distinguished Lecturer, Henry Ford Hospital,1998
  • Honorary Professor, Medical Faculty, University of Heidelberg, 1999-
  • Frederic C. Bartter Award of the American Society for Bone and Mineral Research for Excellence in Clinical Research, 2000

About John Bilezikian

Dr. Bilezikian, the Dorothy L. and Daniel H. Silberberg Professor of Medicine and Professor of Pharmacology at the College of Physicians & Surgeons, Columbia University is Vice Chair of the Department of Medicine for International Education and Research and Chief, Emeritus, of the Division of Endocrinology. He is Director, Emeritus, of the Metabolic Bone Diseases Program at Columbia University Medical Center. Dr. Bilezikian received his undergraduate training at Harvard College and his medical training at the College of Physicians & Surgeons. He completed four years of house staff training (internship, residency and Chief Residency) on the Medical Service at Columbia Presbyterian Medical Center. Dr. Bilezikian received his training in Metabolic Bone Diseases and in Endocrinology at the National Institutes of Health in the Mineral Metabolism Branch under the tutelage of Dr. Gerald Aurbach.

He belongs to a number of professional societies including the American Society of Bone and Mineral Research, of which he served as President (ASBMR), 1995-1996 and the International Society of Clinical Densitometry (ISCD), of which he served as President, 1999-2001. He is a member of the Endocrine Society, the American Federation for Clinical Research, the American Society for Clinical Investigation, the Association of American Physicians, the American Association of Clinical Endocrinologists, the American Society for Pharmacology and Experimental Therapeutics, and the American College of Endocrinology that has designated him Master. He served on the Board of Governors of the International Osteoporosis Foundation (1999-2015) and is a current member of its Committee of Scientific Advisors. He is Chair of the Endocrine Fellows Foundation. He served as Editor-in-Chief of the Journal of Clinical Endocrinology and Metabolism and as Senior Associate Editor of the Journal of Bone and Mineral Research. He is Executive Advisory Editor of Bone Research. His books include Editor-in-Chief of The Parathyroids [1994, 2001, 2015], and co-editor of The Aging Skeleton (1999), Dynamics of Bone and Cartilage Metabolism (1999, 2006), Principles of Bone Biology (1996, 2002, 2008, 2020) and Osteoporosis in Men (2010). He is Editor-in-Chief of the Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism (2019).

He has been on numerous panels, including serving as Chair of the NIH Consensus Development Panel on Optimal Calcium Intake (1994), Co-chair of the last three International Workshops on Primary Hyperparathyroidism (2002, 2008, 2013) and of the first International Workshops on Hypoparathyroidism (2015) and Controversies in Vitamin D (2017, 2018, 2019). Dr. Bilezikian's major research interests are related to the clinical investigation of metabolic bone diseases, particularly primary hyperparathyroidism, hypoparathyroidism and osteoporosis. His studies of parathyroid hormone in these disorders with regard to etiology, clinical manifestations, pathophysiology, mechanisms of skeletal involvement, and therapy are known throughout the world as landmark contributions to our knowledge of these disorders. He has been continuously funded by the NIH since 1974. Over 850 publications speak to these active original investigative initiatives as well as his authorship of many reference sources of endocrinology and metabolic bone diseases.

Dr. Bilezikian is the recipient of the Distinguished Physician Award of the Endocrine Society, the Frederic C. Bartter Award of the ASBMR for Excellence in Clinical Research, and the First Annual Global Leadership Award of the ISCD. In 2009, he received the Gideon A. Rodan Excellence in Mentorship Award from the ASBMR. He received the Laureate Distinguished Educator Award of the Endocrine Society in 2014. In 2014, he was made honorary member of the Brazilian Society of Endocrinology and Metabolism and the Association of Brazilian Orthopedic Osteologists. In 2015, he received the Oscar Gluck Humanitarian Award of the ISCD and the Inaugural Global Educator of the Year Award from McMaster University in Canada. In 2017, he was named Honorary Member of the Russian Osteoporosis Association. Dr. Bilezikian has received Lifetime Achievement and Recognition Awards of the California and Boston Armenian American Medical Societies and the Armenian American Health Professionals Organization (AAHPO). In 2017, he received the Doctor Honoris Causa Award from the Carol Davila School of Medicine in Bucharest, Romania and from the University of Pisa, in Pisa, Italy. He received the Distinguished Physician Award of the American Association of Clinical Endocrinologists in 2018. He received the Ellis Island Congressional Medal of Honor from the United States Government in 2018. Also, in 2018 he received a Parliamentary Medal of Honor from the Government of Armenia for distinguished service and a similar honor from the Government of Brazil. In 2019, he received the Gold Medal for Outstanding Achievements in Medical Research, the highest honor that Columbia University’s College of Physicians and Surgeons bestows on its graduates. In 2020, Dr. Bilezikian received the ASBMR William F. Neuman Award for highest scientific achievement.

Academic Titles

  • Professor of Molecular Pharmacology and Therapeutics at CUMC
  • Dorothy L. and Daniel H. Silberberg Professor of Medicine

Administrative Positions

  • Chief, Division of Endocrinology
  • Director, Metabolic Bone Diseases Program

Committee/Societies/Council Memberships

  • Subspecialty Board on Endocrinology, Diabetes and Metabolism, American Board of Internal Medicine
    1995 - 1995
  • President, American Society of Bone and Mineral Research
    1995 - 1995
  • Chair and Member of the Board, Endocrine Fellows Foundation
    1996 - Present
  • Board of Trustees, National Osteoporosis Foundation
    2001 - 2001
  • Councillor, The Endocrine Society
    2005 - 2005
  • Medical Advisor, Board of Directors, Hypoparathyroidism Association
    2006 - Present
  • Board of Directors, The Paget Foundation
    2006 - Present

Hospital Affiliations

  • NewYork-Presbyterian / Columbia University Irving Medical Center

Gender

  • Male

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NYP Employee Plan
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

AgeWell

  • Medicare Managed Care
  • Special Needs Plan

Capital District Physician Health Plan

  • Capital District Physician Health Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • EPO
  • Medicare Managed Care
  • PPO

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Multiplan

  • Multiplan

MVP Health Care

  • Child/Family Health Plus
  • Essential Plan
  • HMO
  • Medicaid Managed Care

Oxford Health Plans

  • Freedom
  • Liberty

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

1
180 Fort Washington Avenue
New York, New York 10032
Primary

Research

Dr. Bilezikian oversees a very active program of clinical investigation in a number of different metabolic bone diseases. The group of investigators who work with him includes Drs. Ethel Siris (Madeline Stabile Professor of Clinical Medicine and Director, Toni Stabile Osteoporosis Center); Elizabeth Shane (Professor, and Director, Transplantation Bone Disease Program); Shonni Silverberg (Professor), Carolyn Becker (Associate Clinical Professor and Associate Director, Toni Stabile Osteoporosis Center), Etah Kurland (Assistant Professor); and Mishaela Rubin (Instructor). Drs. Bilezikian and Silverberg head the longest and largest prospective study of primary hyperparathyroidism that has ever been conducted. With continuous NIH support, it is now in its twentieth year. With Drs. Silverberg and Rubin, promising new non-surgical approaches to primary hyperparathyroidism are being explored. These investigators have also developed research projects related to the cardiovascular, cognitive, and nutritional aspects of primary hyperparathyroidism. Drs. Bilezikian, Silverberg, and Rubin are also studying a clinical problem that is opposite to that of primary hyperparathyroidism, namely parathyroid hormone deficiency (hypoparathyroidism). Drs. Kurland and Bilezikian are studying osteoporosis in men with particular interests on clinical, histomorphometric, densitometric, genetic and therapeutic elements. Dr. Siris is the medical director of one of the largest epidemiologist surveys of skeletal ever conducted. Dr. Shane (see her separate listing) is one of the pioneers in the investigation of bone loss that occurs after organ transplantation. She is also conducting a study of osteoporosis in premenopausal women. Dr. Becker is heading a study of the patient who has sustained a fragility fracture of the hip. She is interested in the challenges of identifying such patients in an inpatient setting and developing therapeutic approaches with which fracture healing can be accelerated. With Drs. Ronald Katz and Ciao, Dr. Bilezikian conducts a laboratory-based research project focused upon the cellular and biochemical mechanisms of parathyroid hormone and bisphosphonate action.

Research Interests

  • Mechanisms of parathyroid hormone action
  • Metabolic bone diseases
  • Osteoporosis
  • Primary hyperparathyroidism

Grants

S.A. - DEXA SCAN (P&S Industry Clinical Trial)

Mar 16 2017 - Mar 16 2022

13TH FELLOWS FORUM ON OSTEOPOROSIS AND METABOLIC BONE DISEASES (Federal Gov)

Sep 1 2019 - Aug 31 2020

TRAINING PROGRAM IN ENDOCRINOLOGY AND METABOLISM (Federal Gov)

Jul 1 2015 - Jun 30 2020

TRAINING PROGRAM IN ENDOCRINOLOGY AND METABOLISM (Federal Gov)

Jul 1 2015 - Jun 30 2020

PRIMARY HYPERPARATHYROIDISM (Federal Gov)

Apr 1 2014 - Mar 31 2020

12TH FELLOWS FORUM ON OSTEOPOROSIS AND METABOLIC BONE DISEASES (Federal Gov)

Aug 15 2018 - Jul 31 2019

PRIMARY HYPERPARATHYROIDISM (Federal Gov)

Apr 1 2014 - Mar 31 2019

PRIMARY HYPERPARATHYROIDISM (Federal Gov)

Apr 1 2014 - Mar 31 2019

PRIMARY HYPERPARATHYROIDISM (Federal Gov)

Apr 1 2014 - Mar 31 2019

PARADIGHM (PHYSICIANS ADVANCING DISEASE KNOWLEDGE IN HYPOPARATHYROIDISM): A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM (P&S Industry Clinical Trial)

Sep 13 2013 - Sep 13 2018

ELEVENTH FORUM ON OSTEOPOROSIS AND METABOLIC BONE DISEASES FOR FELLOWS IN TRAINING (Federal Gov)

Sep 1 2017 - Aug 31 2018

TENTH FORUM ON OSTEOPOROSIS AND METABOLIC BONE DISEASES FOR FELLOWS IN TRAINING (Federal Gov)

Aug 1 2016 - Jul 31 2017

PROLIA 20090741 (P&S Industry Clinical Trial)

Dec 20 2011 - Dec 20 2016

RACE STUDY/C10-008 (P&S Industry Clinical Trial)

Aug 25 2011 - Aug 25 2016

BONE MATERIAL PROPERTIES IN TYPE 2 DIABETES (Private)

Jul 1 2014 - Jun 30 2016

BONE PROPERTIES IN HYPOPARATHYROIDISM: EFFECT OF PTH (Federal Gov)

Dec 1 2004 - Jun 30 2016

C10-007 (P&S Industry Clinical Trial)

Jun 15 2011 - Jun 15 2016

EIGTH FORUM ON OSTEOPOROSIS AND METABOLIC BONE DISEASES FOR FELLOWS IN TRAINING (Federal Gov)

Aug 12 2014 - Jul 31 2015

CLINICAL BONE MECHANICS USING HR-PQCT AND MRI (Federal Gov)

Jul 1 2010 - Apr 30 2015

A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CINACALCET FOR THE TREATMENT (P&S Industry Clinical Trial)

Apr 15 2010 - Apr 15 2015

EXTENSION PROTOCOL: CONTINUING PTH(1-84) TREATMENT IN HYPOPARATHYROIDISM BEYOND TWO YEARS (P&S Industry Clinical Trial)

Jan 22 2010 - Jan 22 2015

IDENTIFYING RISK FACTORS FOR FRAGILITY FRACTURES AMONG ELDERLY AMENIANS: INITIATING TREATMENT AND PREVENTION STRATEGIES (Private)

Sep 1 2013 - Aug 31 2014

SEVENTH FORUM ON OSTEOPORISIS AND METABOLIC BONR DISEASE FOR FELLOWS IN TRAINING (Federal Gov)

Sep 1 2013 - Aug 31 2014

TREATMENT OF HYPOPARATHYROIDISM WITH PARATHYROID HORMONE (Federal Gov)

Sep 30 2005 - Jul 31 2014

ARANDOMIZED,DOUBLE-BLIND,PLACEBO-CONTROLLED,PIVOTAL STUDY TO INVESTIGATE THE USE OF NPSP 558, A RECOMBINANT HUMAN PARAT (P&S Industry Clinical Trial)

Jun 11 2009 - Jun 11 2014

HORMONAL CONTROL OF PERIOSTEAL EXPANSION (Federal Gov)

Apr 1 2008 - Jan 31 2014

HORMONAL CONTROL OF PERIOSTEAL EXPANSION (Federal Gov)

Apr 1 2008 - Aug 14 2013

6TH FORUM ON OSTEOPOROSIS AND METABOLIC BONE DISEASES FOR FELLOWS IN TRAINING (Federal Gov)

Aug 1 2012 - Jul 31 2013

EFFECTS OF PTH ON THE SKELETON IN HYPOPARATHYROIDISM (P&S Industry Clinical Trial)

Apr 27 2007 - Jun 30 2013

ACTIONS OF AVANDIA (P&S Industry Clinical Trial)

Nov 17 2008 - May 30 2013

COMBINATION RISEDRONATE PARATHYROID HORMONE TRIAL IN MALE OSTEOPOROSIS (IRB# 14225) (P&S Industry Clinical Trial)

Jun 27 2002 - Dec 31 2012

FIFTH FORUM ON OSTEOPOROSIS AND METABOLIC BONE DISEASES FOR FELLOWS IN TRAINING (Federal Gov)

Aug 1 2011 - Jul 31 2012

PRIMARY HYPERPARATHYROIDISM - NON-CLASSICAL MANIFESTATIONS (Federal Gov)

Apr 15 2005 - Mar 31 2012